Background: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of\nthis study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are\nlinked to clinical practice.\nMethods: A non-exhaustive systematic review was conducted according to the three topics. No publication\nrestrictions were imposed and the selected languages were Spanish and English. After that, a summary of the\nmain results and findings of the review was presented and discussed during three meetings (one for each\ntopic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of\npazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist\nmedical oncologists in renal cancer.\nResults: The efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently\nconfirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of\nlife results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of\npatients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly\npatients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with\nconcomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an\neffective drug, in which quality of life (QoL) outcomes are valued above all.\nConclusions: This paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of\npazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and\ntolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to\nbe safe in different patient profiles.
Loading....